Thomas Prebet

Publications (42) View all

• Article: Lenalidomide treatment for patients with myelodysplastic syndrom and low blast count acute myeloid leukemia after azacitidine failure.

  Thomas Prebet, Aude Charbonnier, Véronique Gelsi-Boyer, Marie Joelle Mozziconacci, Didier Blaise, Norbert Vey
  Leukemia & lymphoma 10/2012; · 2.40 Impact Factor
• Article: Outcome of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia.

  Raynier Devillier, Roberto Crocchiolo, Anne Etienne, Thomas Prebet, Aude Charbonnier, Sabine Fürst, Jean El-Cheikh, Evelyne D'Incan, Jérôme Rey, Catherine Faucher, Didier Blaise, Norbert Vey
  [show abstract] [hide abstract]
  ABSTRACT: Abstract Although allogeneic-stem-cell transplantation (Allo-SCT) is an effective treatment for high risk acute myeloid leukemia (AML), relapses remain a major cause of treatment failure. There is currently no standard of care for post-transplant relapse of AML but the increasing numbers of investigational agent in this setting require a better knowledge of their outcome. We retrospectively evaluated the efficacy of salvage therapies in 54 patients with AML relapsing after Allo-SCT. Twenty-four patients received intensive salvage treatment (17 non-intensive chemotherapy, 13 supportive care). CRs were seen only in the group who received intensive salvage (CR rate: 17/24 (71%)). One-year overall survival was 19% (median: 3.4 months) in the whole study group and 33% in the intensive savage group (versus 7% for patients without intensive salvage, p=0.004). Factors influencing OS were, time to relapse after Allo-SCT (HR: 3.7 [1.6-8.8]) and Performance Status (PS) at relapse (HR: 2.2 [1.1-4.4]) by multivariate analysis. Our results confirm the poor prognosis of AML relapse after Allo-SCT. In selected patients, salvage chemotherapy produces CR but these are short lived. Other strategies aiming at modulating immune anti-leukemic activity have to be developed.
  Leukemia & lymphoma 10/2012; · 2.40 Impact Factor
• Article: Outcome of patients with low risk myelodysplasia after azacitidine treatment failure.

  Thomas Prebet, Sylvain Thepot, Steven D Gore, François Dreyfus, Pierre Fenaux, Norbert Vey
  [show abstract] [hide abstract]
  ABSTRACT: -
  Haematologica 09/2012; · 6.42 Impact Factor
• Article: Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.

  Amel Sebaa, Lionel Ades, Fanny Baran-Marzack, Marie-Joelle Mozziconacci, Dominique Penther, Sophie Dobbelstein, Aspasia Stamatoullas, Christian Récher, Thomas Prebet, Soraya Moulessehoul, Pierre Fenaux, Virginie Eclache
  [show abstract] [hide abstract]
  ABSTRACT: TP53 mutations are frequent in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with complex karyotype that include del(5q) and are often associated with deletion of 17p. They have also recently been observed in MDS with isolated del(5q). We assessed the incidence of 17p deletion detected by fluorescence in situ hybridization (FISH) and of TP53 mutations detected by direct sequencing and their correlation and prognostic value in 26 MDS and 17 AML with del(5q). In the 20 cases with isolated del(5q) or one additional abnormality, no 17p deletion was found and 3 of the 18 cases analyzed (17%) had TP53 mutation. In the 23 patients with complex karyotype, 17p deletion was suspected by conventional cytogenetics in 15 cases and confirmed by FISH in 10 of them, while TP53 mutation was found in 8 of the 15 patients tested (53%), only five of whom had 17p deletion. In the whole patient series, TP53 mutations were associated with shorter survival (P = 0.07). We confirm the existence of TP53 mutations in 17% of MDS with isolated del(5q). In patients with del(5q) and complex karyotype, FISH and direct sequencing are complementary techniques to analyze TP53 abnormalities. Our findings also suggest that sequencing of the TP53 gene should be included in the study of patients with del(5q) as a single abnormality or in complex karyotype before lenalidomide treatment. © 2012 Wiley Periodicals, Inc.
  Genes Chromosomes and Cancer 08/2012; 51(12):1086-92. · 3.31 Impact Factor
• Article: Acute leukemia arising after radioiodine treatment for thyroid cancer.

  Marine Gilabert, Thomas Prebet
  Haematologica 08/2012; 97(8):e28-9; author reply e30. · 6.42 Impact Factor